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Abstract
 
Background.
 
Congenital bilateral absence of
the vas deferens (CBAVD) is a form of male infertility in
which mutations in the cystic fibrosis transmembrane con-
ductance regulator 
 
(CFTR)
 
 gene have been identified.
The molecular basis of CBAVD is not completely under-
stood. Although patients with cystic fibrosis have muta-
tions in both copies of the 
 
CFTR
 
 gene, most patients with
CBAVD have mutations in only one copy of the gene.
 
Methods.
 
To investigate CBAVD at the molecular lev-
el, we have characterized the mutations in the 
 
CFTR
 
gene in 102 patients with this condition. None had clini-
cal manifestations of cystic fibrosis. We also analyzed a
DNA variant (the 
 
5T
 
 allele) in a noncoding region of
 
CFTR
 
 that causes reduced levels of the normal CFTR
protein. Parents of patients with cystic fibrosis, patients
with types of infertility other than CBAVD, and normal
subjects were studied as controls.
 
Results.
 
Nineteen of the 102 patients with CBAVD
had mutations in both copies of the 
 
CFTR
 
 gene, and
none of them had the 
 
5T
 
 allele. Fifty-four patients had a
mutation in one copy of 
 
CFTR,
 
 and 34 of them (63 per-
cent) had the 
 
5T
 
 allele in the other 
 
CFTR 
 
gene. In
29 patients no 
 
CFTR
 
 mutations were found, but 7 of
them (24 percent) had the 
 
5T
 
 allele. In contrast, the fre-
quency of this allele in the general population was about
5 percent.
 
Conclusions.
 
Most patients with CBAVD have muta-
tions in the 
 
CFTR 
 
gene. The combination of the 
 
5T
 
 allele
in one copy of the 
 
CFTR 
 
gene
 
 
 
with a cystic fibrosis mu-
tation in the other copy is the most common cause of
CBAVD. The 
 
5T
 
 allele mutation has a wide range of clin-
ical presentations, occurring in patients with CBAVD
or moderate forms of cystic fibrosis and in fertile men.
(N Engl J Med 1995;332:1475-80.)
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C
 
ONGENITAL bilateral absence of the vas deferens
(CBAVD) accounts for at least 6 percent of cases
of obstructive azoospermia and is responsible for 1 to
2 percent of cases of infertility in men.
 
1
 
 CBAVD is also
present in about 95 percent of male patients with cystic
fibrosis, a disorder characterized by chronic pulmonary
disease, pancreatic exocrine insufficiency, and elevated
concentrations of electrolytes in sweat.
 
2
 
Mutations in the cystic fibrosis transmembrane con-
ductance regulator 
 
(CFTR)
 
 gene, which encodes a cy-
clic AMP–regulated chloride channel,
 
3,4
 
 have been
found in patients with cystic fibrosis.
 
5,6
 
 Patients with
the classic form of cystic fibrosis have severe mutations
in each copy of the 
 
CFTR
 
 gene, whereas patients with
a less severe phenotype (i.e., with normal pancreatic
function and mild lung disease) have a severe mutation
in one copy of 
 
CFTR
 
 and a mild mutation in the other,
or mild mutations in both copies.
 
7
 
Mutations in the 
 
CFTR 
 
gene have also been identi-
fied in patients with CBAVD, which suggests that this
condition is a primarily genital form of cystic fibro-
sis.
 
8-12
 
 Thus, patients with CBAVD would be expected,
like all patients with cystic fibrosis, to have two 
 
CFTR
 
mutations. However, few patients with CBAVD have
mutations in both copies of the 
 
CFTR
 
 gene; in the ma-
jority of cases, only one mutation has been found, and
in about a third no mutations have been detected. The
inability of investigators to identify two 
 
CFTR
 
 muta-
tions in these patients, even after analyzing the entire
coding sequence, is not well understood, but it could be
explained by the presence of mutations in noncoding
regions of the gene. Such mutations would produce ab-
normally low levels of CFTR protein, which may cause
obstruction of the vas deferens, but there may be suffi-
cient protein to prevent disease in other organs normal-
ly affected by cystic fibrosis.
Low levels of the CFTR protein could be due to a de-
creased proportion of the normal messenger RNA
(mRNA) of CFTR. Studies of CFTR mRNA in tissue
from normal persons have identified various mRNA
molecules that lack exon 4, 9, or 12.
 
13-17
 
 Whether or not
CFTR mRNA contains exon 9 depends on the variable
length of a DNA sequence of thymines in intron 8 of
 
CFTR
 
 (Fig. 1).
 
18
 
 This sequence, known as a polyT se-
quence, contains five, seven, or nine thymines (the 
 
5T,
7T, 
 
and 
 
9T
 
 alleles, respectively). Since the 
 
5T
 
 allele
causes reduced levels of normal CFTR mRNA,
 
18
 
 this
DNA variant would appear likely to be involved in the
pathogenesis of CBAVD.
To understand the molecular genetics of CBAVD
better, we have characterized the 
 
CFTR
 
 mutations in
patients with this condition and studied the putative in-
volvement of the 
 
5T
 
 allele in CBAVD and other types
of male infertility.
 
M
 
ETHODS
 
Patients
 
We studied 102 unrelated men with azoospermia and CBAVD, as
diagnosed on the basis of scrotal exploration and analysis of semen
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(volume and pH of semen, sperm count, and concentrations of fruc-
tose and citrate). The patients came from Belgium, France, Spain,
and the United States.
 
12,19,20
 
 None had pulmonary or gastrointesti-
nal manifestations of cystic fibrosis. The results of sweat chloride
analysis and additional clinical data on these patients have already
been presented.
 
12,19,20
 
 The diagnoses of CBAVD were initially sug-
gested by the clinical observation of impalpable vasa in the patients
and were subsequently confirmed by analyses of semen and trans-
rectal and abdominal ultrasonography. Each patient had a sperm
count of zero.
 
Control Subjects
 
We studied 186 fathers and 44 mothers of patients with cystic fi-
brosis, each of whom carried a known 
 
CFTR
 
 mutation,
 
21
 
 and 46 nor-
mal subjects from the general population in Spain. We also studied
12 patients with congenital unilateral absence of the vas deferens
(CUAVD) and 10 patients with obstructive azoospermia not due to
CBAVD or CUAVD. The patients with azoospermia but without
CBAVD were in the care of the Andrology Department of the Insti-
tute of Urology, Nephrology, and Andrology in Barcelona, Spain, be-
cause of infertility; those with CUAVD were seen because of infertil-
ity or prostate problems or because they had requested vasectomy.
The mean sperm concentration in the patients with CUAVD was
10.6
 

 
10
 
6 
 
per milliliter (range, 0 to 90
 

 
10
 
6
 
).
 
Analysis of 
 
CFTR
 
 Mutations
 
DNA was isolated from peripheral-blood lymphocytes according
to standard protocols.
 
22
 
 Genomic DNA from the patients with
CBAVD was first analyzed for the most common cystic fibrosis mu-
tation, 
 

 
F508.
 
5
 
 To identify other cystic fibrosis mutations in these
patients, each of the 27 exons of the 
 
CFTR
 
 gene and their flanking
sequences were amplified by the polymerase chain reaction (PCR).
After PCR, all exons were studied by denaturing gradient-gel elec-
trophoresis or by single-strand conformation analysis, as previously
described.
 
23,24
 
The
 
 5T
 
 Allele of Intron 8 of 
 
CFTR
 
We analyzed the frequency of the 
 
5T
 
 allele (the sequence of five
thymines mainly responsible for the absence of exon 9 in CFTR
mRNA) in the general population (i.e., in apparently normal chromo-
somes), fathers and mothers of patients with cystic fibrosis (who car-
ry one chromosome with the cystic fibrosis mutation and one normal
chromosome), and men with CBAVD. To evaluate the incidence of
the 
 
5T
 
 allele of intron 8 in CBAVD and infertility, we studied the fre-
quency of heterozygosity for the allele in patients with CBAVD, pa-
tients with CUAVD, patients with azoospermia but not CBAVD, and
the general population.
Exon 9 was first amplified with primers 9i-5 and 9i-3.
 
25
 
 The PCR
conditions were as follows: denaturation at 95ºC for 30 seconds, an-
nealing at 54ºC for 30 seconds, and extension at 74ºC for 40 seconds,
for 25 cycles. The reaction mixture contained 5
 
 m
 
l of PCR buffer
(N808-0006, Perkin-Elmer Cetus); 200 
 
m
 
M each of deoxyadenosine
triphosphate, deoxycytidine triphosphate, deoxyguanosine triphos-
phate, and deoxythymidine triphosphate; 20 pmol of each primer;
and 1 unit of 
 
Taq
 
 DNA polymerase in a final volume of 50 
 
m
 
l, con-
taining 100 ng of genomic DNA. To amplify the polypyrimidine se-
quence while avoiding the adjacent dinucleotide repeat (GT)n,
 
13
 
 we
performed a nested PCR with primers I9D9 (5
 

 
CCGCCGCTGTGT-
GTGTGTGTGTGTTTTT3
 

 
) and E9R2 (5
 

 
GGATCCAGCAACCG-
CCAACA3
 

 
). The conditions of the nested PCR were as described
above except that 1
 
 m
 
l from the first PCR was used, but for 35 cycles.
The final PCR products were digested with 
 
Xmn
 
I and visualized on
an 8 percent nondenaturing polyacrylamide gel after electrophoresis
for four to five hours at 180 V (Fig. 2).
 
Statistical Analysis
 
Differences between proportions were tested by the chi-square sta-
tistic.
 
26
 
 Yates’ correction for continuity was used in the two-by-two ta-
bles. Relative risks were calculated for the comparison of the patients
with CBAVD with the normal patients. All P values were based on
two-sided comparisons. P values of less than 0.05 were considered to
indicate statistical significance.
 
R
 
ESULTS
 
CFTR
 
 Mutations in CBAVD
 
We studied a group of 102 patients with CBAVD
from Europe and the United States with regard to mu-
tations in the 
 
CFTR
 
 gene. The analysis of the entire
coding sequence allowed us to identify 28 different mu-
tations (Table 1). Most of the mutations have been de-
scribed previously in patients with cystic fibrosis, but
 
Figure 1. DNA Variants in Intron 8 of the 
 
CFTR 
 
Gene and Their
Effects at the mRNA Level.
The region of the 
 
CFTR 
 
gene that includes exons 7 to 10 is
shown at the top. During processing, the sequences not involved
with protein synthesis (introns) are eliminated, and the remaining
sequences (exons) are spliced to form mature mRNA (center
left). The processing of 
 
CFTR
 
 is not completely efficient, be-
cause 10 to 92 percent of transcripts lack exon 9 (bottom left),
depending on the person’s genotype.
 
13,18
 
 When both 
 
CFTR
 
genes bear the 
 
5T 
 
allele (the 
 
5T/5T 
 
genotype), the proportion of
normal CFTR mRNA is reduced to approximately 8 to 12 per-
cent, indicating that the shorter the sequence of thymines in in-
tron 8, the higher the proportion of CFTR mRNA in which exon
9 is lacking.
 
18
GTGTGTTTTTTTTTAAACAG    
GTGTGTTTTTTTAAACAG
GTGTGTTTTTAAACAG
Exon
Exon Exon Exon Exon
Exon Exon Exon
Intron
9T/9T 100
50
10
9T/7T
7T/7T
9T/5T
7T/5T
5T/5T
7
7 8 9 10
7 8 10
8 9 10Intron Intron Intron
Exon Exon Exon
9T
7T
5T
CFTR gene
Normal CFTR mRNA
CFTR mRNA without exon 9
Percentage
of normal
CFTR
CFTR
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Figure 2. PCR Analysis of Alleles in the polyT Sequence of Intron
8 of the CFTR Gene.
Heteroduplex molecules (H) are due to the hybridization of
strands from the 5T, 7T, and 9T alleles (A). The genotypes are
indicated beneath each lane.
1 2 3 4 5 6 7 8 9
A
H
5T 7T 7T 7T 7T
9T 9T 9T 9T 7T
7T 9T 7T 9T
9T 9T 7T 9T
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others have been detected specifically in patients with
CBAVD. Nineteen patients had mutations in both
copies of CFTR (one severe and one mild mutation in
16 patients, and two mild mutations in 3), and 54 pa-
tients had mutations in only one CFTR allele. In 29 pa-
tients, after comprehensive screening, we were unable
to find any mutations in the coding or splice regions of
CFTR.12,19,20
Frequencies of the 5T Allele DNA Variant of Intron 8 of CFTR
In the Spanish population, the frequency of the 5T
allele, which is responsible for abnormal CFTR mRNA,
was similar (5.4 percent) to that previously reported in
other populations (5.2 percent)27-29 (P0.98), and the
populations were pooled for comparative analyses (fre-
quency of the 5T allele in the general population, 5.2
percent). The frequency of the 5T allele in the normal
chromosomes of mothers of patients with cystic fibrosis
(the non–cystic fibrosis chromosomes) was similar (4.5
percent) to that in the general population (P0.87),
but the frequency was lower in the normal chromo-
somes of fathers of patients with cystic fibrosis (2.1 per-
cent) (P0.12). In contrast, the 5T allele was signifi-
cantly more frequent in the chromosomes of patients
with CBAVD (21.1 percent) than in the general popu-
lation (chi-square39.3, P0.001) (Table 2).
The 5T Allele and Infertility
We evaluated the incidence of the 5T allele in men
with various types of infertility. Table 3 shows that
the percentage of patients with CBAVD who had this
allele was significantly higher than that of the general
population (40.2 vs. 10.9 percent) (chi-square11.4,
P0.001, relative risk5.1), whereas the proportion of
patients with CUAVD who had the 5T allele (25 per-
cent) was lower than, but not significantly different
from, the proportion among patients with CBAVD
(P0.48). On the other hand, the proportion of pa-
tients with azoospermia but without CBAVD who had
the 5T allele was similar to that of the general popula-
tion (P0.71).
CFTR Mutations and the 5T Allele in Patients with CBAVD
In most patients with CBAVD, the 5T allele was
strongly associated with the presence of a cystic fibrosis
mutation in the other copy of the CFTR gene (chi-
square9.9, P0.0016), but none of the patients with
CBAVD who had two CFTR mutations carried this al-
lele (Table 4). Two patients were each found to have
two 5T alleles. In one patient one of the alleles was as-
*Minus signs indicate the absence of a CFTR mutation.
†The 5T allele is highlighted for greater visibility.
Table 1. CFTR and polyT Genotypes of 102
Patients with CBAVD.
CFTR GENOTYPE* NO. OF PATIENTS POLYT GENOTYPE†
F508/R668C
F508/D1152H
F508/D1270N
F508/R75L
F508/R117H
F508/L206W
F508/R258G
F508/S1235R
F508/R347H
F508/R347H
R117H/G1349D
R117H/712-1G→T
G149R/R668C
R347H/R1066H
R553X/R668C
R1070W/2869insG
F508/
G542X/
W1282X/
R334W/
K1060T/
R1162X/
N1303K/
A800G/
F508/
F508/
F508/
E115/
R117H/
R347H/
G542X/
R553X/
1677delTA/
2184delA/
27895G→Α/
S1235R/
W1282X/
/
/
/
/
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
22
4
3
1
1
1
1
1
7
1
1
1
1
2
1
1
1
1
1
1
1
3
3
1
19
9T/7T
9T/7T
9T/7T
9T/7T
9T/7T
9T/9T
9T/7T
9T/7T
9T/7T
9T/9T
7T/7T
7T/9T
9T/7T
9T/7T
7T/7T
7T/7T
9T/5T
9T/5T
7T/5T
7T/5T
7T/5T
7T/5T
9T/5T
5T/5T
9T/7T
9T/9T
7T/7T
7T/7T
7T/7T
9T/7T
9T/7T
7T/7T
7T/7T
7T/7T
7T/7T
7T/9T
7T/7T
9T/5T
7T/5T
5T/5T
7T/7T
/ 3 7T/9T
*Data were obtained from the Spanish population analyzed in this study.
†Data were obtained from Kiesewetter et al.,27 Dörk et al.,28 and Cuppens et al.29
‡Includes pooled data from the Spanish population studied and the studies listed above un-
der “Other populations.”
§P0.001 for the comparison with the general population.
¶For these parents, data on the CFTR allele that was not transmitted to the patients with cyst-
ic fibrosis are shown. This allele is considered normal and is conventionally known as the non–
cystic fibrosis chromosome.
P0.87 for the comparison with the general population.
**P0.12 for the comparison with the general population.
Table 2. Frequencies of the polyT Alleles in Intron 8 of CFTR in
Members of the General Population and Subjects with CBAVD,
and in the Non–Cystic Fibrosis Chromosomes of Parents of Pa-
tients with Cystic Fibrosis.
GROUP STUDIED POLYT ALLELE
5T 7T 9T
no. with allele/no. studied (%)
Spanish population*
Other populations†
General population‡
Men with CBAVD
5/92  (5.4)
21/406 (5.2)
26/498 (5.2)
43/204 (21.1)§
76/92  (82.6)
339/406 (83.5)
415/498 (83.3)
97/204 (47.5)
11/92  (12.0)
46/406 (11.3)
57/498 (11.5)
64/204 (31.4)
Parents of patients with
cystic fibrosis¶
Mothers
Fathers
2/44 (4.5)
4/186 (2.1)**
39/44  (88.6)
157/186 (84.4)
3/44  (6.8)
25/186 (13.4)
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sociated with a mild cystic fibrosis mutation,19 whereas
in the other patient no CFTR mutations were identified.
The association between the various CFTR muta-
tions and the 5T allele in the patients with CBAVD was
analyzed by studying the transmission of the mutations
within families (Table 1). Only one CFTR mutation
(A800G) was associated with the 5T allele, whereas all
the others were associated with the 7T or the 9T allele,
confirming that in each patient with CBAVD the 5T al-
lele corresponded to the chromosome that did not car-
ry the CFTR mutation.
DISCUSSION
The main objectives of this study were to determine
whether patients with CBAVD had mutations in the
CFTR gene and to explore whether noncoding sequenc-
es that produce low levels of CFTR mRNA (the 5T al-
lele) were responsible for CBAVD.
Most patients with CBAVD in this study (72 per-
cent) had a mutation in at least one of their CFTR
genes, but only 19 percent had mutations on both chro-
mosomes, with at least one of the two mutations being
mild.12,19,20 Inability to identify the second mutation in
most patients with CBAVD, even after all 27 CFTR ex-
ons were analyzed, suggests that mutations could be lo-
cated elsewhere in the noncoding regions of CFTR.
These mutations may result in a CFTR protein with a
normal structure but low levels of expression,10 which
may cause disease only in the organs most sensitive to
CFTR dysfunction, such as the vas deferens.30,31
The reduced levels of normal CFTR mRNA due to
the deletion of exon 9 depend on the presence of the 5T
allele sequence in intron 8. This nonfunctional CFTR
mRNA accounts for up to 92 percent of the total mRNA
when both CFTR genes have the 5T allele.18 We have
found a significant proportion of men with CBAVD who
have the 5T allele, as compared with men in the general
population, which suggests that this allele functions as
a disease mutation in CBAVD. Similarly, the proportion
of men with CUAVD who have the 5T allele was higher
than in the general population, but lower than among
men with CBAVD. Because CFTR mutations have also
been found in patients with CUAVD,12,19 that condition
could be an incomplete form of CBAVD. In contrast,
the proportion of men with azoospermia but without
CBAVD who had the 5T allele was similar to that in the
general population, suggesting that azoospermia not
due to CBAVD or CUAVD is unrelated to CFTR.
The particular combination of the two CFTR alleles
in a given person (the genotype) results in specific
levels of normal CFTR mRNA and in a specific clini-
cal phenotype (Fig. 3). It has been shown that if nor-
mal CFTR mRNA is present at a level of less than 1 to
3 percent, a severe cystic fibrosis phenotype results32;
if the level is above 8 to 12 percent, the phenotype is
normal18; and at intermediate levels, the phenotype is
one of mild cystic fibrosis.33 Thus, patients with one
cystic fibrosis mutation on one chromosome and the 5T
allele on the other should have abnormally low levels of
normal CFTR mRNA.
The study performed here allows patients with
CBAVD to be classified in five categories (Table 4): pa-
tients with two CFTR mutations (group 1a, 19 percent
of patients with CBAVD); patients with one CFTR
mutation and the 5T allele (group 1b, 33 percent);
patients with only one CFTR mutation (group 2a,
20 percent); patients with only the 5T allele (group
2b, 7 percent); and patients without CFTR mutations
(group 3, 21 percent). Group 1 is completely character-
ized if the 5T allele is a mutation in patients with
CBAVD, whereas in group 2 other, as yet unknown,
mutations in the CFTR gene may be involved. Finally,
in group 3, a gene or genes other than CFTR may be
responsible for CBAVD.
Parents of patients with cystic fibrosis have one nor-
mal CFTR gene and one gene with a cystic fibrosis mu-
tation. Since fathers of patients with cystic fibrosis are
not infertile, if the 5T allele was involved in CBAVD, it
would be expected to be present at a low frequency in
these subjects. Our data show that the frequency of the
5T allele in fathers who carry the cystic fibrosis mutation
is slightly lower than that in both the general population
and mothers who carry the mutation (2.1 percent vs. 5.2
percent and 4.5 percent), reinforcing the hypothesis that
the 5T allele has a role in CBAVD (Table 2).
Four fathers who were carriers of cystic fibrosis had
one CFTR gene with the 5T allele and the other with
a severe cystic fibrosis mutation (G542X, N1303K,
1812-1G→A, or 936delTA). Although these genotypes
should have been associated with CBAVD, these men
had offspring and are clinically normal. Three hypoth-
eses could explain the strong but not complete corre-
lation between the appearance of the 5T allele and
CBAVD. First, there could be a nonrandom associa-
tion between the 5T allele and CBAVD, with the allele
segregating with the CBAVD phenotype but not being
its cause. Second, there could be a partially causal role
for the 5T allele, together with additional mutations in
other parts of the CFTR gene. Third, the 5T allele
could have a causal role in CBAVD, with other factors
accounting for these exceptional men without CBAVD
(the four fathers bearing the cystic fibrosis mutation).
*P0.001 for the comparison with the general population.
†P0.43 for the comparison with the general population.
‡P0.48 for the comparison with patients with CBAVD.
§P0.71 for the comparison with the general population.
Table 3. Frequency of Heterozygosity for the
CFTR 5T Allele among Patients with CBAVD,
CUAVD, or Azoospermia but No CBAVD and
Members of the General Population.
GROUP STUDIED FREQUENCY OF 5T ALLELE
no. with allele/no. studied (%)
Patients
CBAVD
CUAVD
Azoospermia, no CBAVD
41/102 (40.2)*
3/12  (25.0)†‡
1/10 (10.0)§
General population 5/46  (10.9)
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The work presented here argues convincingly against
the first two hypotheses. Nonrandom association is not
the case, since the analysis of several DNA markers
within CFTR in the four fathers and in patients with
CBAVD showed that several haplotypes (combinations
of alleles on the same chromosome) were associated
with the 5T allele (data not shown). The presence of
another mutation in the same CFTR gene as the 5T al-
lele is also excluded, since CFTR was thoroughly ana-
lyzed in all patients with CBAVD and it is extremely
unlikely that all patients with the 5T allele had muta-
tions outside the CFTR coding region. These data and
the association of the 5T allele with low levels of nor-
mal CFTR mRNA18 strongly support the concept that
the 5T mutation generally causes CBAVD when it is
associated with a cystic fibrosis mutation on the other
chromosome.
Additional information about the importance of the
5T mutation was obtained by screening 120 patients
with cystic fibrosis. We identified three adults with the
F508/5T genotype who had mild lung disease start-
ing in their 30s and CBAVD, but no pancreatic disease.
Three other patients, 8, 12, and 14 years of age with
the genotypes E585X/5T and K710X/5T (two were sib-
lings), had a diagnosis of cystic fibrosis due to elevated
concentrations of electrolytes in sweat (	60 mmol per
liter) and episodes of dehydration, but no other clinical
features. Since persons with a cystic fibrosis mutation
and the 5T allele may have levels of normal CFTR
mRNA below the range of 8 to 12 percent (the minimal
level for a normal phenotype18) but above the range of
1 to 3 percent (the level below which severe cystic fibro-
sis occurs31), a wide clinical variation is expected in
them, depending on the variability of levels of normal
CFTR mRNA. These clinical forms should include
CBAVD, moderate cystic fibrosis, and the absence of
fertility problems (Fig. 3). 
In summary, we report the following findings: First,
that the 5T allele in intron 8 of CFTR has clinical ef-
fects related to male infertility. Second, that in 33 per-
cent of cases the CBAVD phenotype results from the
combined action of the 5T allele and a cystic fibrosis
mutation on the other chromosome. In addition, 19 per-
cent of cases of CBAVD are due to the presence of two
CFTR mutations other than the 5T allele. Moreover,
the presence of only one CFTR mutation (without the
5T allele) in 20 percent of patients suggests that other
undetected changes in CFTR may be involved in
CBAVD. Furthermore, the relatively high proportion of
patients with CBAVD who do not have CFTR muta-
tions (22 percent) allows us to propose that another
gene or genes could be responsible for CBAVD. Finally,
CUAVD could be an incomplete form of CBAVD.
A large number of cystic fibrosis mutations have been
discovered during the past five years, and it seems that
we are now better prepared to understand how muta-
tions combine to cause disease. The combination of the
5T allele with a cystic fibrosis mutation in the other
CFTR gene is the most common cause of CBAVD, but
it also has other clinical presentations. Our report on
CFTR mutations in patients with CBAVD indicates that
CBAVD and cystic fibrosis are extreme forms of a wide
Figure 3. Comparison of Percentages of Normal CFTR mRNA,
Clinical Phenotypes, and CFTR Genotypes.
Levels of normal CFTR mRNA depend on the genotype deter-
mining the length of the thymine sequence in intron 8 of CFTR,
the presence of cystic fibrosis mutations, or both. Decreased lev-
els of normal CFTR mRNA may be involved in various clinical
phenotypes, ranging from the normal phenotype to the pheno-
types of CBAVD, cystic fibrosis with pancreatic sufficiency (PS),
and cystic fibrosis with pancreatic insufficiency (PI). Genotypes
that correspond to the combination of a cystic fibrosis mutation
with a 5T allele (CF/5T) have been found in normal persons, pa-
tients with CBAVD, and patients with cystic fibrosis and pancre-
atic sufficiency. Genotypes combining a severe and a moderate
cystic fibrosis mutation (CF/CFM)  or two moderate mutations
(CFM/CFM)  can be involved in either CBAVD or cystic fibrosis
with pancreatic sufficiency (bracket). The delimitation between
the normal, CBAVD, and cystic fibrosis phenotypes and their re-
lations with levels of CFTR mRNA is only approximate. The dis-
tribution of levels of CFTR mRNA in relation to the presence of
the 5T, 7T, and 9T alleles and genotypes is derived from the
work of Chu et al.18
Percentage
of Normal
CFTR mRNA
Clinical
Phenotype
CFTR
Genotype
100
9T/9T
9T/7T
7T/7T
5T/5T
CF/5T
CF M/CF M
CF/CF M
CF/CF
9T/5T
7T/5T
10
0
Normal
CBAVD
Cystic fibrosis-PS
Cystic fibrosis-PI
*Minus signs indicate chromosomes with no mutations when the entire
CFTR coding region was analyzed. CF denotes cystic fibrosis mutation.
†Non-5T alleles denote either 7T or 9T alleles.
‡One patient in this group had the 5T/5T genotype.
§The presence of the 5T allele was strongly associated with heterozy-
gosity for cystic fibrosis mutations (P0.0016).
Table 4. Classification of 102 Patients with CBAVD
According to the Presence or Absence of the
CFTR Mutation and of a polyT Allele at Intron 8.
GROUP
CFTR
GENOTYPE*
POLYT
GENOTYPE†
NO. OF 
PATIENTS (%)
1a
1b
2a
2b
CF/CF
CF/
CF/
/
Non-5T/Non-5T
Non-5T/5T‡
Non-5T/Non-5T
Non-5T/5T‡
19  (18.6)
34§ (33.3)
20  (19.6)
7§ (6.9)
3 / Non-5T/Non-5T 22  (21.6)
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nosologic spectrum of conditions that have a common
molecular basis.
We are indebted to Drs. M. Pritchard and F. Cardellach for useful
suggestions and comments, to H. Kruyer for assistance with the
manuscript, and to J. Giménez, M.D. Ramos, and M. Miranda for
technical assistance.
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